- Home
- PLX vs CMCM Comparison
PLX vs CMCM Comparison
Compare PLX & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CMCM
- Stock Information
- Founded
- PLX 1993
- CMCM 2009
- Country
- PLX United States
- CMCM China
- Employees
- PLX N/A
- CMCM N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CMCM Computer Software: Prepackaged Software
- Sector
- PLX Health Care
- CMCM Technology
- Exchange
- PLX Nasdaq
- CMCM Nasdaq
- Market Cap
- PLX 122.6M
- CMCM 115.1M
- IPO Year
- PLX 1998
- CMCM 2014
- Fundamental
- Price
- PLX $1.40
- CMCM $4.50
- Analyst Decision
- PLX Strong Buy
- CMCM
- Analyst Count
- PLX 1
- CMCM 0
- Target Price
- PLX $15.00
- CMCM N/A
- AVG Volume (30 Days)
- PLX 640.7K
- CMCM 24.2K
- Earning Date
- PLX 08-13-2025
- CMCM 06-19-2025
- Dividend Yield
- PLX N/A
- CMCM N/A
- EPS Growth
- PLX N/A
- CMCM N/A
- EPS
- PLX 0.05
- CMCM N/A
- Revenue
- PLX $59,764,000.00
- CMCM $120,663,543.00
- Revenue This Year
- PLX $65.02
- CMCM $14.27
- Revenue Next Year
- PLX $57.34
- CMCM $39.26
- P/E Ratio
- PLX $28.96
- CMCM N/A
- Revenue Growth
- PLX 0.18
- CMCM 27.02
- 52 Week Low
- PLX $0.82
- CMCM $3.02
- 52 Week High
- PLX $3.10
- CMCM $6.77
- Technical
- Relative Strength Index (RSI)
- PLX 30.38
- CMCM 63.43
- Support Level
- PLX $1.52
- CMCM $3.94
- Resistance Level
- PLX $1.65
- CMCM $4.31
- Average True Range (ATR)
- PLX 0.08
- CMCM 0.18
- MACD
- PLX 0.02
- CMCM -0.00
- Stochastic Oscillator
- PLX 17.19
- CMCM 79.45
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CMCM Cheetah Mobile Inc. each representing fifty (50)
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.